Why Partner

Your Dedicated Platform for T-Cell Engagers for Autoimmune Diseases to Foster New & Existing Relationships with Key Decision Makers Seeking Your Expertise

The 2nd T-Cell Engager for Autoimmune Disease Summit is designed to address the most critical challenges in developing safer, more effective, and clinically differentiated T-cell engagers for autoimmune disease.

As companies increasingly explore the potential of TCEs beyond oncology, the field is entering a new phase of development. Success in autoimmune disease requires more than adapting an oncology TCE platform, developers must account for different disease biology, heterogeneous patient populations, chronic treatment requirements, immune preservation, tissue-specific targets, and the need to achieve deep depletion without compromising long-term safety.

This shift is creating a growing need for trusted technology, platform, service, and strategic partners who understand both T-cell engager development and the unique requirements of autoimmune disease. Developed in close collaboration with autoimmune T-cell engager pioneers across discovery, translational, and clinical development, the summit focuses on advancing progress across key areas, including:

Engineering next-generation T-cell engagers through CD3 tuning, conditional activation, trispecific designs, and immune synapse optimization to improve safety and reduce CRS
Improving translational predictability through humanized models, patient-derived assays, biomarkers, immune profiling, and early clinical data
Enabling precision target discovery beyond conventional B-cell depletion, including peptide-HLA targets, plasma cells, and autoreactive immune-cell populations
Overcoming biological barriers including tissue penetration, T-cell exhaustion, target accessibility, and achieving deep and durable immune-cell depletion
Supporting clinical development through dose optimization, PK/PD, biomarker strategies, CRS management, and long-term safety monitoring
Differentiating autoimmune TCE programmes through regulatory, competitive, and commercial strategies as the therapeutic landscape becomes increasingly crowded

Partner with us in 2026 to position your organization at the forefront of this rapidly evolving field and connect directly with 80+ senior discovery, translational, preclinical, clinical, and business development leaders actively working to advance autoimmune TCE programmes.

Whether you offer TCE platforms, novel targeting technologies, translational models, biomarker solutions, analytical capabilities, clinical development expertise, or strategic services, the summit provides an opportunity to demonstrate how your solutions can help companies overcome the unique challenges of translating TCEs into effective autoimmune therapies , and build partnerships with the teams shaping the next generation of the field.

Download Brochure

Powering Innovation in T-Cell Engager for Autoimmune Disease Research

Attendees from leading biopharma and biotech companies are actively seeking partners with expertise in T-cell engager engineering, translational science, biomarker development, immune profiling, and clinical development. Partnering with the 2nd T-Cell Engager for Autoimmune Disease Summit connects you directly with the decision-makers developing the next generation of autoimmune T-cell engager therapies.

This is where solution providers meet the leaders shaping safer, more effective autoimmune T-cell engager pipelines from discovery through clinical development.

Integrated CROs & CDMOs

Autoimmune T-cell engager developers require integrated partners to accelerate programs from discovery through clinical development. Showcase your expertise in antibody engineering, cell line development, analytical characterization, GMP manufacturing, and CMC support to help developers streamline development, reduce risk, and bring next-generation T-cell engagers to the clinic faster.

Specialised Antibody Discovery Platforms

As developers seek safer and more selective autoimmune T-cell engagers, innovative antibody discovery technologies are critical for identifying differentiated binders and novel formats. Demonstrate how your platform enables rapid discovery, optimization, and engineering of bispecific, trispecific, and next-generation immune engager molecules.

Antibody & Protein Providers

Developers rely on high-quality recombinant proteins, antibodies, antigens, and assay reagents to support target validation, screening, and translational research. Position your portfolio as an essential resource for accelerating autoimmune T-cell engager discovery and preclinical development.

Advanced Formatting Specialists

Next-generation autoimmune T-cell engagers require increasingly sophisticated molecular architectures to balance efficacy with safety. Highlight your expertise in advanced protein engineering, multispecific formats, half-life extension, Fc engineering, and developability optimization to help developers create differentiated therapeutic candidates.

Autoimmune Models

Predictive preclinical models are essential for evaluating efficacy, cytokine release, and immune-cell depletion before entering the clinic. Demonstrate how your humanized models, patient-derived systems, organoids, and autoimmune disease platforms improve translational confidence and accelerate successful clinical development.

Hear What Our Past Sponsors Have to Say

Smaller group, poster session with opportunity to network

COO, Structura Biotechnology

The caliber of the attendees was very high, and the meeting content was excellent

Project Leader, Evotec

Available Inventory

We have a range of inventory from standard booth and speaking slots to more bespoke deliverable such as badges, exclusive dinners and tours to help elevate your brand.